Elizabeth Budde, MD, PhD

A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.

A panel of experts discuss the role of odronextamab.

A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.

A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.

A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART

A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.

Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.

Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.

Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.

An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.

Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.

Medical experts highlight second-line options for treating patients with DLBCL.

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.